Petros pharmaceuticals successfully launches ai tool in collaboration with multi-billion-dollar software provider

Petros begins enrollment in ai integrated human factors study to optimize self-screening, continuing its efforts to make stendra (avanafil) the first erectile dysfunction medication to achieve otc status (please see important safety information below) new york, ny / accesswire / march 19, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces it has successfully launched its artificial intelligence (ai) tool developed as a result of its collaboration with a multi-billion-dollar software developer. the tool is being integrated into the company's web app being used for patient self-screening, which it is testing in its recently launched human factors study.
PTPI Ratings Summary
PTPI Quant Ranking